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Many studies have described macromolecular conjugates
designed to deliver antitumour agents lysosomotropically
(Trouet et al., 1972; Duncan et al., 1981; Hoes et al., 1986;
Monsigny et al., 1980). Such conjugates should be stable in
the extracellular environment, but degrade intralysosomally
via pH mediated hydrolysis or enzymatic cleavage to liberate
the cytotoxic drug. Recently, it has been demonstrated that
the binding of the antitumour agents doxorubicin (DOX) or
daunorubicin (DNM) to inert N-(2-hydroxypropyl)metha-
crylamide (HPMA) copolymers, via a lysosomally degradable
tetrapeptide sequence (glycine-phenylalanine-leucine-glycine),
can afford a substantial elevation in drug therapeutic index
(Duncan et al., 1989; Cassidy et al., 1989). HPMA copolymer
conjugates are particularly amenable to synthetic manipula-
tion, enabling the incorporation of cytotoxic drugs, and bio-
functional moieties, such as antibodies (Rihova & Kopecek,
1985), sugars (Duncan et al., 1983) or hormones (O'Hare et
al., 1990), to potentiate site specific drug delivery.
Pendant galactosamine residues have been shown to ele-
vate deposition of HPMA-DOX in liver, via an interaction
with hepatocyte cell surface receptor (Duncan et al., 1986;
Seymour et al., 1990); one such formulation being recently
accepted for phase I/II clinical trial as a potential treatment
for hepatocellular carcinoma and metastatic disease residing
in the liver. The pharmacokinetics of galactose targeted
HPMA-DOX have been studied in detail (Seymour et al.,
1990), but the intracellular pharmacokinetics of these con-
jugates are of considerable importance, both to elucidate
their mechanisms of action and to understand whether such
materials may be useful for the circumvention of multidrug
resistance (MDR), a clinical phenomenon to which free
anthracyclines are particularly susceptible (Kaye & Merry,
1985).
To follow the intracellular distribution of a lysosomally
degradable HPMA conjugate, a HPMA copolymer was syn-
thesised to contain 3HDNM and pendant galactosamine
residues (Figure 1).
Either the HPMA copolymer containing 3HDNM or free
3HDNM was administered intra-femorally to male Wistar
rats (180 to 250g) under anaesthesia (Halothane), at a non
receptor saturating dose of 0.075 mg kg-' (respective to
DOX content). After various times, up to 48 h, the liver was
subject to subcellular fractionation. Rats were starved for
24 h prior to liver removal (to deplete glycogen reserves), but
allowed water ad libitum. At each time interval the liver was
perfused via the hepatic portal vein using 3 x 10 ml of ice
cold 0.25 M sucrose containing 1 mM EDTA (as anticoag-
ulant), immediately excised, blotted dry and weighed before
being pushed through a wire mesh (1 mm2). The pulp was
then reweighed, resuspended in 0.25 M sucrose (approxi-
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mately 10 ml g-' wet weight of tissue) and homogenised
using a 30 cm3 Potter-Elvjhem tube and a Tri-R stirrer
(5 x 10s up and down strokes). An initial slow spin (250
g x 5 min: 4°C) was employed to remove whole cells from the
homogenate. Recovered homogenate was subjected to differ-
ential centrifugation (de Duve et al., 1955). Nuclear (7,000
g x min), mitochondrial (33,000g x min), lysosomal (210,000
g x min) and microsomal (3,000,000g x min) enriched frac-
tions were prepared and the final supernatant represented the
cytosolic fraction. Each pellet was resuspended in 0.25 M
sucrose (2-3 ml), and 0.5 ml samples removed in triplicate
for liquid scintillation counting with appropriate standardisa-
tion.
The gradient was initially calibrated using assays for pro-
tein (Smith et al., 1985), 5'-nucleotidase (Avruch & Wallach,
1971), lactate dehydrogenase (Lowry et al., 1957), mitochon-
drial reductase (Pennington, 1961), hexosaminidase (Barrett
& Heath, 1977) and DNA (Kapuscinski & Skoczylas, 1977).
Because the primary interest of this study was focussed on
the lysosomal processing of the polymer conjugate each
experiment was routinely calibrated using the following
assay.
Hexosaminidase assay
The lysosomal marker, hexosaminidase, was assayed accord-
ing to Barrett & Heath (1977), in which a sample from a
homogenised fraction (50fil) was added to 250jil of a citrate/
phosphate buffer (0.25 M; pH 5) containing 0.1% (v/v)
Triton-X-100, and allowed to equilibrate at 37°C. 4-Methy-
umbelliferyl-2-acetamido-2-deoxy-4-D-glucopyranoside (100)Al)
was then added for 1 min, followed by the addition of
sodium bicarbonate (1 M; 2 ml) to stop the reaction. Samples
were read on a Perkin-Elmer Fluorimeter (Ex 365 nm, Em
450 nm).
Comparison
From the total liver uptake shown in Figure 2a, it is readily
apparent that within the first hour, liver accumulation of the
conjugated 3HDNM is 3-fold greated than that obtained with
free 3HDNM. As a percentage of the initial dose administer-
ed, these recoveries represent approximately 15% and 5%
respectively. Twenty-four hours after application, free
3HDNM has almost completely disappeared from the liver.
In comparison, retention of polymer-DNM was significantly
prolonged, 62% of the 1 h value being retained at 48 h.
Rapid removal of free DNM from liver over 24 h has been
previously reported in rats by Yesair et al. (1972), who
attributed disappearance to metabolism (primarily conversion
to daunorubicinol) and extensive biliary excretion, 11% of an
intravenous dose (10 mgkg-') appearing in bile within the
first 24 h.
The intracellular pharmacokinetics of free and polymer
bound 3HDNM, may be compared by analysis of the relative
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Figure 1 Structure of HPMA copolymer containing DNM. The HPMA copolymer - 3HDNM was synthesised essentially as
described previously using a two step procedure (Duncan et al., 1988). First a reactive polymer precursor was prepared containing
methacryloylated p-nitrophenyl ester to which galactosamine and 3HDNM were subsequently bound by aminolysis. The product
had a specific activity of approximately 1.45 1Ci mg-' and a weight average molecular weight of 20,000.
drug accumulation in each organelle-enriched fraction. Maxi-
mum accumulation of 3HDNM, was found in the nuclear
(Figure 2b) and lysosomal-enriched fractions (Figure 2d).
This localisation correlates with in vitro studies, in which
anthracycline accumulation was found to be confined to
these two compartments (Noel et al., 1978; Peterson &
Trouet, 1978). Such a distribution is thought to involve rapid
nuclear binding until 'saturation' occurs, followed by accum-
ulation in lysosomes. Nuclear accumulation of DNM is a
product of its intrinsic affinity for DNA, intercalation being
proposed as the principal mode by which the anthracyclines
exert their therapeutic effect (Di Marco, 1975). This is corro-
borated by recent in vitro microspectrofluorometry studies,
which indicated that the nuclear levels of some anthracyclines
are directly proportional to the extent of growth inhibition
(Gigli et al., 1989). The observation that anthracyclines are
sequestered in lysosomes may be related to their weak basic-
ity (Zenebergh et al., 1984); many weak bases accumulate in
lysosomes since the acidic environment facilitates their pro-
tonation (Ohkuma & Poole, 1978), producing species to
which the lysosomal membrane is less permeable (De Duve et
al., 1974). Relatively high free drugs levels were also observed
in mitochondria (Figure 2e), perhaps due to interaction with
mitochondrial DNA or alternatively due to presence of lyso-
somes in this fraction, since the distribution of hexosaminidase
(Figure 3) suggests a significant degree of contamination.
There were several significant differences in subcellular dis-
tribution of DNM following administration as copolymer-
conjugate: (i) a greater initial percentage of lysosomally
associated drug (approximately five times that obtained with
free drug 3HDNM), followed by progressive lysosomal loss
(Figure 2d), (ii) a continual increase in drug detected in the
cytoplasmic fraction, accounting for a 3-fold elevation in
drug levels over 48 h (Figure 2f), and (iii) neither the nuclear
nor mitochondrial levels fell rapidly within the 48 h period.
The changes observed in nuclear and mitochondrial drug
accumulation were not directly comparable with those of the
lysosomal profile, unlike those of the microsomally enriched
fraction which were (Figure 2e) and could therefore be attri-
buted purely to lysosomal contamination. All these observa-
tions would be consistent with pinocytic internalisation of
polymer-DNM, lysosomal cleavage of drug from the tetra-
peptide linkage and subsequent release into the intracellular
milieu, free drug then being available for concentration
dependent binding to nuclear and mitochondrial DNA. Such
a phenomenon must be governed by a series of chemical548 S.R. WEDGE et al.
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Figure 2 Subcellular distribution of radioactivity in the liver
following intravenous administration of free and polymer-bound
3HDNM. The radioactivity recovered is expressed as ng DNM/
wet weight liver (g) following administration of free 3HDNM
(0 O) or polymer-bound 3HDNM (@ 0) respectively.
Data represent the mean (± s.e.) of at least three replicate
animals.
equilibria: intralysosomal and cytosolic drug concentration,
lysosomal membrane permeability, and the associated trans-
membrane pH gradient.
If we are to assume that nuclear DNA intercalation is of
primary importance in expression of anthracycline cytotox-
icity, analysis of nuclear accumulation would be most perti-
nent to a consideration of therapeutic indices. The observed
nuclear levels of DNM, following administration of polymer-
conjugate, were greater than those obtained with free
3HDNM, particularly after 24-48 h (Figure 2b). This differ-
ence is a result of elevated liver accumulation and/or sus-
tained lysosomotropic release of drug. Tentatively therefore,
one may presume that the greater therapeutic efficacy of the
anthracycline copolymer-conjugate seen in vivo, may correlate
with enhanced nuclear deposition. However, there is evidence
to suggest that the mechanism of anthracycline cytotoxicity is
not simply restricted to DNA intercalation. The relatively
high and sustained mitochondrial levels, measured after
administration ofcopolymer-conjugate may also be ofimpor-
tance as anthracyclines are known to inhibit mitochondrial
respiration (Goormaghtigh et al., 1986; Nicolay et al., 1987)
and induce peroxidation of mitochondrial membrane lipids
(Griffin-Green et al., 1988).
Since the percentage distribution of hexosaminidase
remained unaltered with time (Figure 3), there was no evid-
ence for lysosomal disruption by anthracycline mediated free
radical generation, as suggested by Singal et at. (1988). The
DNM used in these experiments only amounted to a non
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Figure 3 Hexosaminidase activity in subcellular fractions of the
liver. Enzyme recovery is shown 1 h (LI ), 24 h ( M ) or 48 h
( = ) after administration of polymer 3HDNM (panel a) or free
3HDMN (panel b) respectively. Data represent the mean (± s.e.)
of at least three replicate animals.
receptor saturating 'trace' dose, but it has been shown
previously that HPMA copolymer conjugate bearing DNM
(10 mg kg' with respect to DNM) can be administered to
rats without altering transaminases or alkaline phosphatase
levels in serum (McCormick, 1986).
Potentially, these formulations may prove useful for cir-
cumvention of multidrug resistance. The principal develop-
ment change associated with MDR is the over expression of
a 170 kDa membrane glycoprotein (Endicott & Ling, 1989),
able to mediate the active expulsion of anthracyclines (and
other natural cytotoxic drugs) as soon as they enter the cell,
thus preventing their intracellular accumulation. Also MDR
cells have been shown to display increased rates ofmembrane
trafficking (Sehested et al., 1987). Attachment of drug to a
macromolecular carrier restricts its mode of cellular uptake
to the endocytic route. Use of a copolymer drug conjugate
should therefore bypass resistance at the membrane level,
and it has been shown here that subsequent lysosomal release
can provide a sustained intracellular concentration of drug,
giving a more propitious gradient for cytotoxic action even
perhaps with MDR cells. Recent reports have shown that
nanoparticle entrapped doxorubicin (Kubiak et al., 1989) and
neocarzinostatin bound to the copolymer styrene-maleic acid
(Miyamoto et al., 1990) are active against MDR cell lines in
vitro.
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